A Clinical Review of the Larger-Than-Dates Uterus

Definition

A "uterus larger than dates" is a crucial clinical sign, not a standalone diagnosis. It is identified when the symphysio-fundal height (SFH) measurement, taken from the pubic symphysis to the uterine fundus, is more than 3 centimeters greater than the expected gestational age in weeks (2). This simple bedside measurement serves as a vital screening tool. After 20-24 weeks of gestation, the SFH in centimeters should closely correlate with the gestational age in weeks. A significant discrepancy is a trigger for a systematic and thorough investigation to uncover the underlying cause, which can range from a benign dating error to significant maternal or fetal pathology (3). It is important to remember that SFH measurement accuracy can be affected by factors such as maternal obesity, a full bladder, the presence of uterine fibroids, and inter-operator variability, reinforcing its role as a screening, rather than diagnostic, tool (4).

Epidemiology

Understanding the local Malaysian context is crucial for refining the differential diagnosis and maintaining a high index of clinical suspicion for certain conditions.

  • Fetal Macrosomia: Globally, macrosomia (birth weight >4000g) affects 3-15% of pregnancies. In Malaysia, maternal diabetes (pre-existing or GDM) is a critical predictor. A 2013 study identified key local risk factors including maternal age, BMI, excessive gestational weight gain, parity, and paternal BMI (37). Furthermore, a 2024 Malaysian study highlighted that Malay neonates have a higher mean birth weight compared to Chinese, Indian, and Orang Asli neonates. This finding is clinically significant as it underscores the importance of using ethnicity-specific growth charts rather than a single universal threshold to define LGA, thereby preventing both over-investigation and missed diagnoses (38).

  • Gestational Diabetes (GDM): Malaysia has a high age-adjusted prevalence of diabetes (16.7% in adults) (42). This makes GDM and its sequelae a frequent cause of a size-date discrepancy in local practice. Clinicians should be particularly vigilant for the "diabetic dyad" of pathology, where maternal hyperglycemia simultaneously causes both fetal macrosomia and polyhydramnios, compounding the uterine overdistension.

  • Molar Pregnancy: The incidence is notably higher in women of Asian ethnicity. A Malaysian tertiary centre reported an incidence of 2.6 per 1,000 deliveries, which is significantly higher than the ~1 per 1,000 rate reported in Western populations (44). For the Malaysian houseman, this statistic is not just academic; it means that molar pregnancy must be considered a more prominent differential diagnosis and should be actively ruled out, especially when presented with first-trimester bleeding and a significant size-date discrepancy.

  • Uterine Fibroids: Found in 2-11% of pregnancies, fibroids are more common in women of Asian ethnicity compared to their white counterparts (17, 48). With the societal trend of delayed childbearing in Malaysia, more women are entering pregnancy with pre-existing fibroids. This increases the likelihood of encountering symptomatic fibroids (e.g., pain from red degeneration) or fibroids large enough to contribute to a larger-than-dates uterus (46).

Etiology

The causes of a larger-than-dates uterus can be remembered with the practical mnemonic "Wrong Dates, Big Baby, More Fluid, More Babies, Molar, Myomas." A structured approach to these differentials is key.

  • Incorrect Gestational Age: The most frequent and most easily correctable cause. It often arises from an inaccurately recalled Last Menstrual Period (LMP), irregular cycles, or recent hormonal contraceptive use. Confirming the date is always the first step (1).

  • Fetal Macrosomia: An excessively large fetus (Estimated Fetal Weight >90th percentile) is a major contributor to increased uterine size and carries significant intrapartum risks (2).

  • Polyhydramnios: Excessive amniotic fluid (Amniotic Fluid Index >25 cm) distends the uterus beyond its expected size and can be a marker for underlying maternal or fetal issues (15).

  • Multiple Gestation: The presence of twins, triplets, or more naturally leads to a larger uterine volume and requires specialized antenatal care (1).

  • Uterine Pathology: Most commonly uterine leiomyomas (fibroids), which can enlarge significantly under the hormonal influence of pregnancy and contribute to the overall uterine size (4).

  • Gestational Trophoblastic Disease (GTD): A hydatidiform mole (molar pregnancy) involves rapid, abnormal placental tissue proliferation and is a crucial diagnosis to make due to its potential for malignant transformation (3).

Pathophysiology

Fetal Macrosomia

The primary mechanism, especially in diabetic mothers, is the Pedersen Hypothesis.

  1. Maternal hyperglycemia results in the free transfer of glucose across the placenta, leading to fetal hyperglycemia.

  2. The fetal pancreas responds by producing excess insulin (fetal hyperinsulinemia).

  3. Insulin acts as a powerful growth hormone in the fetus. This anabolic state stimulates generalized somatic growth, accelerates fat deposition (adiposity), and promotes glycogen storage. This results in a baby that is not only large but has a characteristic body composition with a higher fat-to-lean mass ratio and disproportionately larger shoulders and abdomen compared to the head, a key factor predisposing to the obstetric emergency of shoulder dystocia (8). In non-diabetic mothers, maternal obesity and excessive weight gain can lead to increased levels of other nutrients like amino acids and free fatty acids, which also stimulate fetal insulin and growth factors like IGF-1, driving fetal growth.

Polyhydramnios

This results from an imbalance in amniotic fluid homeostasis, where fluid production exceeds removal. Near term, a fetus produces 500–1200 mL of urine and swallows 210–760 mL of fluid daily (15).

  • Increased Production:

    • Maternal Diabetes: Fetal hyperglycemia induces an osmotic diuresis in the fetal kidneys, leading to fetal polyuria and a subsequent increase in amniotic fluid volume (14).

    • Fetal High-Output States: Conditions that increase fetal cardiac output also increase renal blood flow and urine production. Examples include severe fetal anemia (from rhesus isoimmunization, parvovirus B19) and certain fetal tumors like sacrococcygeal teratomas (14).

  • Impaired Removal:

    • Gastrointestinal Obstruction: Anatomic blockages like esophageal or duodenal atresia (associated with Trisomy 21) prevent the fetus from swallowing amniotic fluid and absorbing it through the gut (14).

    • Neuromuscular Disorders: Swallowing is a complex process. Neurological disorders like anencephaly disrupt the swallowing reflex, leading to severe polyhydramnios (14).

Hydatidiform Mole

This is caused by a fundamental error in fertilization, leading to an abnormal genetic composition.

  • Complete Mole: Results from the fertilization of an anucleated ("empty") ovum. The resulting conceptus is diploid but entirely of paternal genetic origin (androgenetic). In the absence of essential maternal genes, no viable fetus develops (18).

  • Partial Mole: Occurs when a normal ovum is fertilized by two sperm, resulting in a triploid conceptus (e.g., 69,XXY). An abnormal, non-viable fetus may be present (18).

  • The abnormal paternal-dominant genome triggers excessive, disorganized proliferation of the trophoblast. The chorionic villi become grossly swollen (hydropic), creating the classic "bunch of grapes" appearance. This tissue produces enormous quantities of human chorionic gonadotropin (hCG). The hCG molecule shares a structural similarity with TSH, and at very high concentrations, it can stimulate the TSH receptor, leading to clinical hyperthyroidism (19).

Uterine Fibroids

These benign smooth muscle tumors are exquisitely hormone-sensitive. Fibroid cells have a higher concentration of estrogen and progesterone receptors than normal myometrium, making them hyper-responsive to the hormonal surges of pregnancy. If a fibroid's growth outstrips its blood supply, the central part can become ischemic, leading to aseptic necrosis known as "red degeneration," a common cause of acute, localized, and severe abdominal pain during pregnancy (35).

Clinical Presentation

Diagnostic Clues

  • Molar Pregnancy: The classic triad of first-trimester vaginal bleeding, hyperemesis gravidarum (severe nausea/vomiting), and pre-eclampsia developing before 20 weeks gestation is highly suggestive and driven by hCG excess (18, 19).

  • Polyhydramnios: The uterus feels tense, globular, and fluid-filled. Fetal parts are difficult to palpate, and the fetus may be easily "ballottable" (pushed away and then felt returning). A fluid thrill may be elicited (25).

  • Uterine Fibroids: The uterus may have a firm, irregular, or "knobbly" contour on palpation, representing the distinct masses of the fibroids (6).

  • Multiple Gestation: Palpation of three or more large fetal parts (poles) or the clear detection of two separate fetal heart rates with a rate difference of >10 bpm is diagnostic (6).

Common Symptoms

  • Abdominal tightness or a sensation of excessive pressure.

  • Shortness of breath (dyspnea), as the overdistended uterus pushes up on the diaphragm, especially with severe polyhydramnios.

  • Generalized uterine discomfort or Braxton-Hicks contractions.

⚠️ Red Flag Signs & Symptoms

  • Passage of grape-like vesicles: This is pathognomonic for a molar pregnancy and requires immediate definitive management (19).

  • Early-onset pre-eclampsia (<20 weeks): This sign is almost exclusively associated with molar pregnancy and signals a high level of trophoblastic disease (19).

  • Severe, localized, and constant abdominal pain: May indicate red degeneration of a fibroid, a diagnosis of exclusion that can cause significant maternal distress (31).

  • Tense, tender abdomen with associated respiratory distress: Suggests severe, symptomatic polyhydramnios that requires urgent intervention (amnioreduction) to relieve maternal symptoms and reduce the risk of preterm labor (25).

Complications

  • Maternal:

    • Postpartum Hemorrhage (PPH): There is a high risk with macrosomia, polyhydramnios, and multiple gestation. The uterine muscle fibers are overstretched and may fail to contract effectively after delivery (atony), leading to life-threatening hemorrhage (7, 14).

    • Preterm Labour: Increased risk from uterine overdistension and irritability in cases of polyhydramnios and multiple gestation (15).

    • Operative Delivery: Higher rates of caesarean section (due to failed induction, obstruction, or malpresentation) and instrumental delivery (12).

    • Gestational Trophoblastic Neoplasia (GTN): A malignant sequela of molar pregnancy where molar tissue persists, invades the myometrium, or metastasizes. It occurs in ~15-20% of complete moles and ~5% of partial moles (26).

  • Fetal/Neonatal:

    • Shoulder Dystocia: A major obstetric emergency with fetal macrosomia, where the anterior shoulder becomes impacted behind the pubic symphysis. It can lead to permanent brachial plexus injury (Erb's palsy) or severe hypoxic brain injury (8).

    • Birth Trauma: Increased risk of fractures (clavicle, humerus) and soft tissue injuries in macrosomic infants during a difficult vaginal delivery (71).

    • Umbilical Cord Prolapse: A high risk with polyhydramnios, especially during spontaneous or artificial rupture of membranes, as the gush of fluid can carry the cord down ahead of the presenting part (14).

    • Neonatal Hypoglycemia: Common in infants of diabetic mothers. The chronic fetal hyperinsulinemia persists for a few days after birth, but the maternal glucose supply is cut off, leading to a rapid drop in neonatal blood sugar (8).

Prognosis

  • Fetal Macrosomia/Polyhydramnios: The prognosis is generally good with appropriate antenatal surveillance and a well-managed delivery. Strict glycemic control in GDM is key. The outcome hinges on avoiding birth trauma and promptly managing neonatal complications like hypoglycemia.

  • Uterine Fibroids: The vast majority of women have uneventful pregnancies. The main risk is pain from red degeneration, which is typically self-limiting with conservative management and does not usually affect fetal outcome (45).

  • Molar Pregnancy: The prognosis is excellent, but this is entirely contingent on correct diagnosis and diligent follow-up. The standard treatment, suction curettage, is highly effective. Even for the minority of cases that progress to GTN, chemotherapy is highly curative, with success rates approaching 100% for low-risk disease. Patient compliance with the follow-up protocol is therefore paramount (19).

Differential Diagnosis

  • Fetal Macrosomia: This is a key differential, especially with risk factors like GDM or obesity. On examination, a single, large, firm fetus is felt. It is distinguished from polyhydramnios, where the uterus feels more fluid-filled than solidly large. It is confirmed by ultrasound showing an EFW >90th percentile with a normal or mildly increased amniotic fluid volume (2).

  • Polyhydramnios: Consider this if the uterus feels unusually tense and fetal parts are difficult to palpate. It is often associated with GDM or fetal anomalies. It is distinguished from macrosomia by the characteristic fluid-filled feel and is confirmed by an ultrasound showing an AFI >25 cm (15).

  • Molar Pregnancy: This must be considered, given its higher incidence in Malaysia. It is distinguished clinically by a history of first-trimester bleeding, severe hyperemesis, and the absence of fetal heart tones. An ultrasound showing a characteristic intrauterine "snowstorm" appearance without a viable fetus is diagnostic for a complete mole (18, 44).

Investigations

Immediate & Bedside Tests

  • Symphysio-Fundal Height (SFH) Measurement: The initial screening test that identifies the size-date discrepancy and triggers the diagnostic pathway (2).

  • Urine Dipstick: A simple but vital test to screen for proteinuria (a sign of pre-eclampsia, especially relevant in suspected molar pregnancy) and glycosuria (suggesting possible undiagnosed diabetes).

Diagnostic Workup

  • First-Line Investigation: Obstetric Ultrasound

    • This is the single most important investigation to accurately differentiate the cause.

    • Purpose: The sonographer performs a systematic assessment to confirm viability, establish accurate dating via fetal biometry (crown-rump length or head circumference), assess fetal size (EFW), measure amniotic fluid volume (AFI/DVP), visualize the number of fetuses, evaluate placental morphology (looking for the heterogeneous, cystic "snowstorm" appearance of a mole), and assess uterine anatomy for the size, number, and location of fibroids (4).

  • Gold Standard:

    • Molar Pregnancy: The definitive diagnosis is not made by ultrasound alone but is established by histopathological examination (HPE) of the products of conception obtained after uterine evacuation (18).

  • Diagnostic Blood Tests:

    • Glucose Tolerance Test (GTT): Essential if ultrasound reveals fetal macrosomia or polyhydramnios, to unmask underlying GDM, which is a treatable cause of both conditions (8).

    • Serum β-hCG: Mandatory if a molar pregnancy is suspected. Levels are pathologically elevated, often exceeding 100,000 mIU/mL, in a complete mole, serving as a crucial tumor marker for diagnosis and follow-up (16).

    • Maternal Blood Group & Antibody Screen: This is performed in cases of polyhydramnios to rule out rhesus or other blood group isoimmunization, which can cause fetal anemia, hydrops, and a high-output state leading to polyhydramnios (67).

Management

Management Principles

Management is directed at the specific underlying cause, not the size discrepancy itself. The goals are to mitigate associated maternal and fetal risks, optimize pregnancy outcomes, and provide comprehensive counseling to ensure shared decision-making. The first and most crucial step is always to confirm the gestational age, ideally based on a first-trimester ultrasound, to rule out a simple dating error (57).

Definitive Therapy

Fetal Macrosomia

  • Antenatal: The only intervention shown to potentially slow the rate of fetal growth is strict maternal glycemic control in women with GDM, achieved through diet, exercise, and, if necessary, pharmacological therapy with metformin or insulin (8).

  • Delivery: This is highly controversial due to the imprecision of EFW by ultrasound.

    • Induction of Labour (IOL): Routine IOL at 38-39 weeks is not generally recommended by major bodies like ACOG. While it may reduce birth weight and fracture risk, it has not been shown to reduce the rate of shoulder dystocia but may increase the rate of caesarean section for failed induction (12). The decision requires careful counseling.

    • Elective Caesarean Section (CS): This must be discussed with the patient. ACOG guidelines suggest prophylactic CS may be considered if the EFW is ≥5,000g in a non-diabetic woman or ≥4,500g in a diabetic woman, reflecting the need to balance surgical risks against the risk of severe birth trauma (10).

    • Intrapartum: Maintain high vigilance. Ensure experienced staff are present for the delivery. Be prepared for shoulder dystocia drills (e.g., HELPERR mnemonic). Actively manage the third stage of labour with oxytocics to prevent PPH from uterine atony.

Polyhydramnios

  • Antenatal:

    • Amnioreduction: This therapeutic amniocentesis is reserved for severe, symptomatic cases with maternal respiratory distress or risk of preterm labor. It provides temporary relief but carries risks (PPROM, abruption, infection) and the fluid often re-accumulates (15).

    • Indomethacin: An NSAID that reduces fetal urine output. Its use is limited to short courses (<72 hours) and is contraindicated after 32 weeks of gestation due to the significant risk of causing premature constriction or closure of the fetal ductus arteriosus, leading to fetal pulmonary hypertension (67).

  • Delivery:

    • Timing is individualized based on cause and severity. Plan delivery at a tertiary centre with NICU access.

    • Perform a controlled artificial rupture of membranes (ARM), allowing fluid to drain slowly (e.g., by puncturing with a fetal scalp electrode needle), to prevent the sudden decompression that can lead to umbilical cord prolapse or placental abruption.

Uterine Fibroids

  • Antenatal: The vast majority are managed conservatively and expectantly.

    • Pain Management for Red Degeneration: This involves admission for bed rest, hydration, and adequate analgesia (Paracetamol is first-line). Opioids may be required. NSAIDs can be used cautiously for short periods before 32 weeks (17).

    • Antepartum Myomectomy: This is extremely rare and carries a high risk of catastrophic hemorrhage from the hypervascular pregnant uterus. It is reserved for exceptional circumstances like a torsed pedunculated fibroid causing intractable pain (34).

  • Delivery: Vaginal delivery is the goal unless a large fibroid in the lower uterine segment physically obstructs the birth canal or causes a persistent fetal malpresentation (e.g., transverse lie), which would be an indication for CS. Caesarean myomectomy is generally avoided due to hemorrhage risk (34).

Hydatidiform Mole

  • Definitive Management: This is an urgent diagnosis requiring prompt and definitive action.

    • Surgical Evacuation: The standard of care is suction dilatation and curettage (D&C) to completely evacuate all molar tissue. This should be performed promptly by a senior clinician, with blood products available and ideally under ultrasound guidance to ensure completeness and reduce perforation risk (19).

    • Hysterectomy: Can be a primary treatment option for older women who have completed their family, as it removes the mole and virtually eliminates the risk of local persistent disease (18).

  • Long-Term Plan & Patient Education:

    • Mandatory GTD Registration & Follow-up: All patients diagnosed with a molar pregnancy must be registered with a national or regional GTD center for expert oversight of the mandatory follow-up protocol. This involves serial serum β-hCG measurements until levels normalize and remain so for a specified period (e.g., 6 months for a complete mole).

    • Effective contraception is essential during the follow-up period to avoid a new pregnancy, which would confound hCG monitoring. Hormonal contraception can be started safely after evacuation (78).

When to Escalate

Call Your Senior (MO/Specialist) if:

  • The patient presents with signs of severe pre-eclampsia (persistent headache, visual disturbances, epigastric pain, high BP) before 20 weeks gestation, as this is a hallmark of molar pregnancy.

  • An ultrasound report suggests a molar pregnancy or GTD. The patient requires urgent specialist review and planning for evacuation.

  • A patient with a known fibroid develops acute, intractable abdominal pain unresponsive to simple analgesia, to rule out red degeneration or other pathology.

  • A patient with polyhydramnios develops severe respiratory distress or signs of preterm labor.

  • During labour with suspected macrosomia, there is an arrest of descent in the second stage, as this may signal impending shoulder dystocia.

Referral Criteria:

  • Refer to a tertiary centre for all cases of severe polyhydramnios, multiple gestation, and confirmed molar pregnancy, as these require multidisciplinary care.

  • Refer to the designated GTD follow-up centre immediately after a histopathological diagnosis of a molar pregnancy is made.

  • Refer to the Maternal-Fetal Medicine (MFM) specialist for complex cases, such as polyhydramnios with a suspected fetal anomaly, consideration for amnioreduction, or management of severe fetal anemia.


References

  1. Valley Perinatal Services. (n.d.). What It Means When Your Uterus Measures Too Big or Too Small. Retrieved July 14, 2025, from https://valleyperinatal.com/uterine-size-discrepancy/

  2. Karlsen, A. F., et al. (2015). Diagnostic accuracy of fundal height and handheld ultrasound-measured abdominal circumference to screen for fetal growth abnormalities. Acta Obstetricia et Gynecologica Scandinavica, 94(7), 752-757. https://pmc.ncbi.nlm.nih.gov/articles/PMC4465094/

  3. Wikipedia. (n.d.). Fundal height. Retrieved July 14, 2025, from https://en.wikipedia.org/wiki/Fundal_height

  4. Mayo Clinic. (n.d.). Fundal height: An accurate sign of fetal growth? Retrieved July 14, 2025, from https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/expert-answers/fundal-height/faq-20057962

  5. Tadi, P., & Lui, F. (2024). Gestational Age Assessment. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK526000/

  6. Mayo Clinic. (n.d.). Fetal macrosomia. Retrieved July 14, 2025, from https://www.mayoclinic.org/diseases-conditions/fetal-macrosomia/symptoms-causes/syc-20372579

  7. Cleveland Clinic. (n.d.). Fetal Macrosomia: Risk Factors, Complications & Management. Retrieved July 14, 2025, from https://my.clevelandclinic.org/health/diseases/17795-fetal-macrosomia

  8. American College of Obstetricians and Gynecologists. (2016). Practice Bulletin No. 173: Fetal Macrosomia. Obstetrics & Gynecology, 128(5), e195-e209.

  9. American Academy of Family Physicians. (2001). Management of Suspected Fetal Macrosomia. American Family Physician, 63(2), 302-307. https://www.aafp.org/pubs/afp/issues/2001/0115/p302.html

  10. Kady, S., & Nassar, A. H. (2023). Polyhydramnios. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK562140/

  11. Hamza, A., et al. (2013). Polyhydramnios: Causes, Diagnosis and Therapy. Geburtshilfe und Frauenheilkunde, 73(12), 1241-1246. https://pmc.ncbi.nlm.nih.gov/articles/PMC3964358/

  12. Johns Hopkins Medicine. (n.d.). Symptoms and Diagnosis of Multiple Pregnancy. Retrieved July 14, 2025, from https://www.hopkinsmedicine.org/health/conditions-and-diseases/staying-healthy-during-pregnancy/symptoms-and-diagnosis-of-multiple-pregnancy

  13. High Risk Pregnancy Info. (n.d.). Fibroids in Pregnancy. Retrieved July 14, 2025, from https://www.highriskpregnancyinfo.org/fibroids-in-pregnancy

  14. Al-Hussaini, T., & Tadi, P. (2024). Hydatidiform Mole. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459155/

  15. Merck Manual Professional Version. (n.d.). Molar Pregnancy. Retrieved July 14, 2025, from https://www.merckmanuals.com/professional/gynecology-and-obstetrics/abnormalities-of-pregnancy/molar-pregnancy

  16. Texas Children's Hospital. (n.d.). Polyhydramnios. Retrieved July 14, 2025, from https://www.texaschildrens.org/content/conditions/polyhydramnios

  17. Mayo Clinic. (n.d.). Molar pregnancy. Retrieved July 14, 2025, from https://www.mayoclinic.org/diseases-conditions/molar-pregnancy/symptoms-causes/syc-20375175

  18. Better Health Channel. (n.d.). Molar pregnancy. Retrieved July 14, 2025, from https://www.betterhealth.vic.gov.au/health/healthyliving/molar-pregnancy

  19. BabyCenter. (n.d.). Fibroids and pregnancy: Causes, symptoms, and treatment. Retrieved July 14, 2025, from https://www.babycenter.com/pregnancy/health-and-safety/uterine-fibroids_7187

  20. Fibroid.com. (n.d.). Fibroids & Pregnancy. Retrieved July 14, 2025, from https://www.fibroid.com/about-fibroids/fibroids-pregnancy/

  21. De, A., & Vancaillie, T. (2022). Uterine fibroids in pregnancy. CMAJ, 194(22), E775. https://www.cmaj.ca/content/194/22/E775

  22. Tan, P. C., et al. (2013). Factors influencing macrosomia in pregnant women in a tertiary care hospital in Malaysia. The Southeast Asian journal of tropical medicine and public health, 44(5), 794-803. https://pubmed.ncbi.nlm.nih.gov/24147966/

  23. Mohd-Zin, S. W., et al. (2024). Maternal height, and ethnicity and birth weight: A retrospective cohort study of uncomplicated term vaginal deliveries in Malaysia. Malaysian Journal of Medicine and Health Sciences, 20(1), 160-167.

  24. Mobula, L. M., et al. (2021). ILSI Southeast Asia symposium: prevalence, risk factors, and actions to address gestational diabetes in selected Southeast Asian countries. Nutrition reviews, 79(Suppl 2), 60-76.

  25. Cheah, P. L., & Looi, L. M. (2012). Outcome of molar pregnancies in Malaysia: a tertiary centre experience. The Malaysian journal of pathology, 34(2), 117-122. https://pubmed.ncbi.nlm.nih.gov/23445147/

  26. Ciavattini, A., et al. (2016). Contemporary Management of Fibroids in Pregnancy. Reviews in Obstetrics and Gynecology, 9(3-4), 146-154. https://pmc.ncbi.nlm.nih.gov/articles/PMC2876319/

  27. Abdul Karim, A. K., et al. (2021). Glassy cell carcinoma of the right cervix on uterine didelphys with right renal agenesis: A rare case report. Malaysian Journal of Medicine, 76(S3), A-17-18.

  28. Kaiser Permanente. (n.d.). Uterine fibroid incidence differs by race, ethnicity. Retrieved July 14, 2025, from https://divisionofresearch.kaiserpermanente.org/uterine-fibroid-incidence-differs-by-race-ethnicity/

  29. The ObG Project. (n.d.). When LMP and Ultrasound Dates Don't Match: When to Redate? Retrieved July 14, 2025, from https://www.obgproject.com/2023/01/02/accurate-ultrasound-pregnancy-dating/

  30. Patient.info. (n.d.). Polyhydramnios (Causes, Symptoms, and Treatment). Retrieved July 14, 2025, from https://patient.info/doctor/polyhydramnios

  31. National Institute for Health and Care Excellence. (2021). Induction of labour for suspected fetal macrosomia. In NICE guideline [NG207]. https://www.ncbi.nlm.nih.gov/books/NBK579534/

  32. National Health Service. (n.d.). Molar pregnancy. Retrieved July 14, 2025, from https://www.nhs.uk/conditions/molar-pregnancy/

Previous
Previous

Polyhydramnios: A Clinical Review

Next
Next

A Clinical Guide to the Small-for-Dates Uterus